Eric Mark Green - 06 Aug 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Signature
/s/ Louis Lalli
Issuer symbol
WST
Transactions as of
06 Aug 2024
Net transactions value
-$7,173,713
Form type
4
Filing time
08 Aug 2024, 16:16:53 UTC
Previous filing
02 Jul 2024
Next filing
02 Oct 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $1,832,856 +30,732 +19% $59.64 192,640 06 Aug 2024 Direct F1
transaction WST Common Stock Sale $9,364,409 -30,732 -16% $304.71 161,898 06 Aug 2024 Direct F1, F2
transaction WST Common Stock Options Exercise $357,840 +6,000 +3.7% $59.64 167,898 06 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -30,732 -84% $0.000000 6,000 06 Aug 2024 Common Stock 30,732 $59.64 Direct F3
transaction WST Stock Option (Right to Buy) Options Exercise $0 -6,000 -100% $0.000000* 0 06 Aug 2024 Common Stock 6,000 $59.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.
F2 The price reported in Column 4 is a weighted average price.
F3 This option is fully vested.